$100+ Billion spent on myriad of acquisitions across Pharma and Biotech industries in H1 2018
Lloyd Price
JULY 5, 2018
That deal gave Sanofi two hemophilia drugs Eloctate for Hemophilia A and Alprolix for Hemophilia B. In January Sanofi also gained control of fitusiran, an RNAi therapeutic in development for hemophilia A and B through its partnership with Alnylam. In April New Haven, Conn.-based France-based Sanofi plunked down $11.6
40 
Let's personalize your content